249 related articles for article (PubMed ID: 31134150)
1. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.
Ferrata M; Schad A; Zimmer S; Musholt TJ; Bahr K; Kuenzel J; Becker S; Springer E; Roth W; Weber MM; Fottner C
Front Oncol; 2019; 9():343. PubMed ID: 31134150
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract][Full Text] [Related]
3. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
4. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
Hasegawa S; Kobayashi N; Okubo N; Tokuhisa M; Goto A; Kurita Y; Sato T; Hosono K; Endo I; Nakajima A; Ichikawa Y
Intern Med; 2021 Apr; 60(7):977-983. PubMed ID: 33162477
[TBL] [Abstract][Full Text] [Related]
5. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
Kim ST; Ha SY; Lee S; Ahn S; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim KM; Park YS
J Cancer; 2016; 7(5):484-9. PubMed ID: 26958083
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms.
Liu M; Hu W; Zhang Y; Zhang N; Chen L; Lin Y; Wang Y; Luo Y; Guo Y; Chen M; Chen J
Front Oncol; 2022; 12():917743. PubMed ID: 36203421
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System.
Xing J; Ying H; Li J; Gao Y; Sun Z; Li J; Bai C; Cheng Y; Wu H
Front Oncol; 2020; 10():132. PubMed ID: 32181153
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E
PLoS One; 2020; 15(12):e0243900. PubMed ID: 33315908
[TBL] [Abstract][Full Text] [Related]
11. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
13. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
[TBL] [Abstract][Full Text] [Related]
14. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
15. Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8+ T-cell infiltration in small cell carcinoma of the esophagus: a retrospective analysis of 34 years of National Cancer Center data in China.
Zhang C; Zhang G; Xue L; Zhang Z; Zeng Q; Wu P; Wang L; Yang Z; Zheng B; Tan F; Xue Q; Gao S; Sun N; He J
Int J Surg; 2023 Mar; ():. PubMed ID: 36974732
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data.
Rösner E; Kaemmerer D; Sänger J; Lupp A
Transl Oncol; 2022 Nov; 25():101526. PubMed ID: 36067541
[TBL] [Abstract][Full Text] [Related]
17. Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment.
Busse A; Mochmann LH; Spenke C; Arsenic R; Briest F; Jöhrens K; Lammert H; Sipos B; Kühl AA; Wirtz R; Pavel M; Hummel M; Kaemmerer D; Baum RP; Grabowski P
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228231
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
20. Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
Centonze G; Lagano V; Sabella G; Mangogna A; Garzone G; Filugelli M; Belmonte B; Cattaneo L; Crisafulli V; Pellegrinelli A; Simbolo M; Scarpa A; Spaggiari P; Brambilla T; Pusceddu S; Prinzi N; Anichini A; Tripodo C; Milione M
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33920514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
